Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Maruzen Pharmaceuticals Co. Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 4 distinct examiners and 4 distinct art units, indicating separate examination assignments across the docket.
KUCHARCZK, JED A is the busiest examiner, with 1 pending matter. Since no examiner carries more than that figure, counsel should evaluate each action independently while coordinating positions on related pharmaceutical subject matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCHARCZK, JED A | 1 | 80.4% | +16.3% |
| MELLER, MICHAEL V | 1 | 47.2% | +28.0% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864263 | PARASYMPATHETIC NERVE ACTIVATION AGENT AND PARASYMPATHETIC NERVE ACTIVATION COMPOSITION | KUCHARCZK, JED A | — |
| 18846440 | ANTI-OBESITY AGENT AND ANTI-OBESITY COMPOSITION | MELLER, MICHAEL V | — |
| 18560211 | ORAL COMPOSITION, SKIN COSMETIC AND HAIR COSMETIC | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864263 | PARASYMPATHETIC NERVE ACTIVATION AGENT AND PARASYMPATHETIC NERVE ACTIVATION COMPOSITION | KUCHARCZK, JED A | — |
| 18846440 | ANTI-OBESITY AGENT AND ANTI-OBESITY COMPOSITION | MELLER, MICHAEL V | — |
| 18560211 | ORAL COMPOSITION, SKIN COSMETIC AND HAIR COSMETIC | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1655 | 1 |
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864263 | PARASYMPATHETIC NERVE ACTIVATION AGENT AND PARASYMPATHETIC NERVE ACTIVATION COMPOSITION | KUCHARCZK, JED A | 1623 | §101§102Other | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18846440 | ANTI-OBESITY AGENT AND ANTI-OBESITY COMPOSITION | MELLER, MICHAEL V | 1655 | §101§102§103 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18701698 | AMPK ACTIVATOR, MOTOR FUNCTION IMPROVING AGENT, MUSCULAR ENDURANCE IMPROVING AGENT, AND MUSCLE ATROPHY PREVENTING AGENT | YOO, SUN JAE | 1621 | — | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18560211 | ORAL COMPOSITION, SKIN COSMETIC AND HAIR COSMETIC | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103 | Final Rejection | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaruzen Pharmaceuticals Co. Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jed A Kucharczk has the most, with 1 of Maruzen Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
